By

phillipsandphillips
Myeloma New Zealand is today calling on Pharmac to make good on their proposal to widen access to blood cancer treatment lenalidomide (Revlimid) from April this year, allowing eligible patients access the subsidised drug earlier in their course of treatment. As one of several groups that marched on Parliament in 2019 presenting petitions demanding an...
Continue Reading
Media Release In a move welcomed by patient advocacy group Myeloma New Zealand, drug buying agency Pharmac has proposed to widen access to blood cancer treatment lenalidomide (Revlimid).  Myeloma is an incurable type of blood cancer that starts in the bone marrow and leads to serious complications such as kidney failure, bone pain and infections....
Continue Reading
Highlights include: • Once-weekly vs twice weekly carfilzomib for newly diagnosed MM • Negative trials for pembrolizumab in treatment naive and relapsed/refractory MM • Daratumumab plus dexamethasone in triple refractory MM Download here: Multiple Myeloma Research Review Issue 32
Continue Reading
A summary of events and the status of medicines applications for myeloma currently with Pharmac   Tania Crosbie Special Projects Manager, Myeloma New Zealand   Despite advertising that Pharmac would be responding to the Health Select Committee (HSC) with regards to the myeloma petition at the Wednesday October 23rd HSC meeting, no oral feedback was...
Continue Reading
Go along in person or watch live on Facebook (see details below) as Pharmac presents their oral submission at the Committee’s meeting on Wednesday, 23 October 2019, from approximately 08.30am to 09.50am, at Parliament Buildings in Wellington. They will address all of the following petitions in one submission. Petition of Jeffrey Chan: Ask Pharmac to...
Continue Reading
Close relatives of people with blood cancer are more likely to be diagnosed with the disease themselves, a major study has found. An international team, led out of the Institute of Cancer Research in London, examined diagnosis, birth and death records of more than 150,000 people with all types of blood cancer — such as leukaemia, lymphoma or myeloma...
Continue Reading
Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma Research Review Issue 31
Continue Reading
For those who are able to, including family and friends, we urge you to join us on Tuesday 7 May in Wellington to march for the RIGHT TO LIVE. We’ll be presenting our petition at the steps of Parliament to ask that the drugs that extend or improve the quality of lives are funded by...
Continue Reading
To date, the choice of therapy for an individual multiple myeloma patient has been based on clinical factors such as age and comorbidities. The widespread evolution, validation, and clinical utilization of molecular technologies, such as fluorescence in situ hybridization and next-generation sequencing has enabled the identification of a number of prognostic and predictive biomarkers for...
Continue Reading
1 2 3 4 5

Floor 7, 90 The Terrace
Wellington Central
New Zealand